Assessment of safety and feasibility of human allogeneic adipose-derived mesenchymal stem cells in a pediatric patient

To the Editor: Human adipose-derived mesenchymal stem cells (hAd-MSC) have been the subject of many investigations and has attracted significant attentions as to their potential therapeutic applications.^1,2,3 Ad-MSC possess pleuripotential properties capable of differentiating into several types of cells such as adipocyte, myocyte, chondrocyte, and osteocyte.⁴ Intravenous administration of Ad-MSC showed accumulation mainly in the lungs, and also in the heart, liver, and brain.⁵ MSC has been used to help alleviate various disease conditions. Long-term follow-up of patients with ischemic stroke after MSC administration showed some improvement with no adverse effects after 5 years.⁶

On the other hand, cerebral palsy (CP) is a heterogenic disability of varied etiology. CP is a severe disabling disease with a worldwide incidence of two to three per 1000 live births.⁷ CP involves impaired movement, muscle function, and cognitive functioning, with effects ranging from mild to severe. No biological intervention has been effective for CP, and the standard approach is limited to supportive management. Currently, stem cell-based strategies have garnered attention due to their ability to stimulate neuroregeneration and neuroprotection in CP.^8,9,10,11

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD